Skip to main content
. 2015 Sep 4;10(11):2002–2012. doi: 10.2215/CJN.01700215

Figure 3.

Figure 3.

Receiver-operating characteristic (ROC) curve analyses of in vitro rADAMTS13 secretion (A) and residual activity (B) levels of mutations found in patients developing or not developing acute renal impairment during bouts. Dotted lines in the graphs represent the 95% confidence bounds. rADAMTS13, recombinant a disintegrin and metalloprotease with thrombospondin motifs 13; 95% CI, 95% confidence interval.